Eric Bednarski has joined MVM Life Science Partners as a partner. He will be based in the firm's
MVM is pleased to announce that Dr Eric Bednarski has joined MVM Life Science Partners as a partner. Eric will be based in the firm's Boston office.
Eric's experience in starting, building and monitoring biopharmaceutical companies will enhance MVM's investment capacity as it launches its third life science fund, MVM Fund III L.P.
Previously, Eric was a partner at Advent Healthcare Ventures, a spin-out of the life science venture team of Advent International where he focused on investments in biopharmaceutical companies for over six years. Eric was a co-founder, CEO and board member of Advent portfolio companies Ampla Pharmaceuticals, Inc. and Prexa Pharmaceuticals, Inc. He also shared responsibility for Advent's lead investments in Aegerion Pharmaceuticals, Inc. and AlgoRx Pharmaceuticals, Inc. (now Anesiva, Inc.).
Prior to joining Advent, Eric was Director in the Corporate Finance Group of Silicon Valley Bank where he provided M&A and finance advisory services to VC-backed life science companies.
Eric carried out doctoral and post-doctoral research on treatment strategies for Alzheimer's disease and ageing at the University of California, Irvine. Eric has a PhD from the University of California and a BS degree in Neural Sciences from Brown University. Eric was also in the drug discovery group of Dupont-Merck Pharmaceutical Company.
MVM has worked closely with Eric for several years, both in the investigation of new investment opportunities and in the development of shared investments such as Aegerion Pharmaceuticals, Inc.
MVM Life Science Partners LLP, founded in 1997, is a leading Life Science venture capital firm that manages three funds with over US$500 million under management. MVM invests across the Life Sciences markets in biopharmaceuticals, diagnostics, drug delivery, gene therapy, medical devices, OTC medicines, research tools and vaccines. MVM invests predominantly in start up and early stage companies based across Europe and in the US. The MVM team operates from offices in London and Boston.
For more information: www.mvmlifescience.com